Neuro-inflammatory risk factors for treatment failure in "early second stage" sleeping sickness patients treated with pentamidine.

Lejon V Legros D Savignoni A Etchegorry MG Mbulamberi D Büscher P
Journal of neuroimmunology 2003 Nov ; 144(1-2); 132-8. doi: . Epub 2004 03 02

Abstract

In a clinical trial on efficacy of Pentamidine in second stage Trypanosoma brucei gambiense patients with /=4 and LATEX/T.b. gambiense positive CSF, were associated with treatment failure. Detection of intrathecal IgM synthesis is valuable for assessment of brain involvement and treatment decision.